WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong
· Delayed Price · Currency is HKD 23.25
-0.85 (-3.53%)
May 6, 2025, 4:08 PM HKT
WuXi Biologics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 3,356 | 3,400 | 4,420 | 3,388 | 1,689 | Upgrade
|
| Depreciation & Amortization | 1,437 | 1,169 | 800.67 | 481.78 | 303.01 | Upgrade
|
| Other Amortization | 24.43 | -73.88 | 32.36 | 90.49 | 13.27 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.46 | 3.48 | 19.27 | 0.87 | 2.66 | Upgrade
|
| Loss (Gain) From Sale of Investments | 91.72 | -13.83 | -379.44 | -665.44 | -371.44 | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | - | -2.63 | Upgrade
|
| Stock-Based Compensation | 1,216 | 1,274 | 1,234 | 531.92 | 276.37 | Upgrade
|
| Provision & Write-off of Bad Debts | 151.78 | 319.97 | 258.53 | 156.67 | 121.06 | Upgrade
|
| Other Operating Activities | -258.43 | -514.84 | 130.08 | 409.82 | 217.16 | Upgrade
|
| Change in Accounts Receivable | 161.93 | -1,038 | -1,500 | -1,441 | -1,402 | Upgrade
|
| Change in Inventory | 201.85 | 442.46 | -498.12 | -783.19 | -704.52 | Upgrade
|
| Change in Accounts Payable | 375.38 | -162.34 | -509.02 | 741.85 | 747.17 | Upgrade
|
| Change in Unearned Revenue | -1,313 | -317.2 | 1,633 | 1,071 | 987.85 | Upgrade
|
| Change in Other Net Operating Assets | -226.69 | 178.41 | -100.14 | -551.77 | 4.23 | Upgrade
|
| Operating Cash Flow | 5,217 | 4,668 | 5,542 | 3,431 | 1,881 | Upgrade
|
| Operating Cash Flow Growth | 11.77% | -15.77% | 61.51% | 82.39% | 55.73% | Upgrade
|
| Capital Expenditures | -3,930 | -4,046 | -5,868 | -6,508 | -6,025 | Upgrade
|
| Sale of Property, Plant & Equipment | 87.33 | 196.86 | 20.13 | 80.86 | 66.49 | Upgrade
|
| Cash Acquisitions | - | - | -131.49 | -2,181 | -155.24 | Upgrade
|
| Sale (Purchase) of Intangibles | - | -10 | - | - | - | Upgrade
|
| Investment in Securities | -387.97 | 596.39 | -253.24 | -1,428 | -1,153 | Upgrade
|
| Other Investing Activities | 288.56 | 34.07 | 324.74 | 433.9 | 50.6 | Upgrade
|
| Investing Cash Flow | -3,942 | -3,228 | -5,908 | -9,602 | -7,216 | Upgrade
|
| Long-Term Debt Issued | 1,129 | 1,097 | 2,389 | 675.28 | 1,171 | Upgrade
|
| Total Debt Issued | 1,129 | 1,097 | 2,389 | 675.28 | 1,171 | Upgrade
|
| Long-Term Debt Repaid | -818.68 | -1,916 | -2,684 | -822.11 | -349.86 | Upgrade
|
| Total Debt Repaid | -818.68 | -1,916 | -2,684 | -822.11 | -349.86 | Upgrade
|
| Net Debt Issued (Repaid) | 309.96 | -818.45 | -295.02 | -146.83 | 821.38 | Upgrade
|
| Issuance of Common Stock | 19.39 | 26.16 | 36.18 | 11,035 | 5,649 | Upgrade
|
| Repurchase of Common Stock | -1,766 | -916.92 | -2,804 | -2,517 | - | Upgrade
|
| Other Financing Activities | -1,314 | 3,670 | 471.7 | -161.91 | 95.39 | Upgrade
|
| Financing Cash Flow | -2,750 | 1,961 | -2,592 | 8,209 | 6,566 | Upgrade
|
| Foreign Exchange Rate Adjustments | 83.98 | -125.99 | 350.11 | -131.5 | -340.4 | Upgrade
|
| Net Cash Flow | -1,391 | 3,275 | -2,608 | 1,908 | 890.24 | Upgrade
|
| Free Cash Flow | 1,288 | 622.14 | -326.72 | -3,077 | -4,144 | Upgrade
|
| Free Cash Flow Growth | 106.97% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 6.89% | 3.65% | -2.14% | -29.90% | -73.83% | Upgrade
|
| Free Cash Flow Per Share | 0.30 | 0.14 | -0.07 | -0.70 | -0.98 | Upgrade
|
| Cash Interest Paid | 200.61 | 217.28 | 108.24 | 83.2 | 82.54 | Upgrade
|
| Cash Income Tax Paid | 1,092 | 782.53 | 585.66 | 349.99 | 94.24 | Upgrade
|
| Levered Free Cash Flow | -2,296 | -320.31 | -594.39 | -3,720 | -5,981 | Upgrade
|
| Unlevered Free Cash Flow | -2,198 | -221.25 | -554.16 | -3,696 | -5,954 | Upgrade
|
| Change in Net Working Capital | 3,811 | 1,143 | -465.59 | 319.63 | 1,469 | Upgrade
|
Updated Sep 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.